Davide Ferrari

In my opinion OpenEvidence has basically ended the need for UpToDate, however, some disagree. Can we at least all agree that there is virtually no role now for medical book chapters, reviews etc… that are obsolete the second they are finally published.

I’m going to halve my publication output. You should consider slow science, too nature.com/articles/d4158…

🆕🗞️ A Vaccine💉for cancer🦀interception. A preventative approach aiming to reduce cancer incidence by targeting precancers and early-stage cancers. For patients with Lynch syndrome. Out @NatureMedicine📰 Paradigm↩️intervene early✅ #Cancer @OncoAlert nature.com/articles/s4159…

Is it sexy? No. Is it incredibly important for how we treat patients? Absolutely 🧠🧬 For over 20 years, 6 months of oxaliplatin plus a fluoropyrimidine has been the default for stage III colon cancer, and often high-risk stage II and rectal cancer. The cost has always been cumulative neuropathy that can follow patients for life ⚡️🖐️ The SCOT trial, the largest study in the IDEA collaboration, gives us long-term clarity with nearly 6,100 patients and more than 6 years of follow-up: 📊 5-yr DFS identical with 3 vs 6 months: 72.9% vs 72.9% 📈 5-yr OS identical: 82.4% vs 82.4% ✅ Noninferiority for OS formally met for 3 months Where this really matters clinically: 🟢 CAPOX clearly supports 3 months 🟢 Low-risk stage III shows no OS penalty 🟡 Even high-risk disease sees only tiny absolute OS differences ⚠️ Meanwhile, neuropathy nearly doubles when oxaliplatin is extended to 6 months. Many patients pay a lifelong price for minimal benefit. SCOT also uniquely included rectal cancer patients treated with upfront surgery, and here too, 3 months held up. This fits perfectly with modern TNT strategies 🧩 Takeaway: This isn’t flashy, but it’s foundational. For most patients with localized colon or rectal cancer, 3 months of adjuvant CAPOX is enough. Six months should be the exception, not the rule, and always a shared decision 🤝 Sometimes the most important advance is knowing when to stop. @OncoAlert @TheGutOncLab #GI26 ascopubs.org/doi/pdf/10.120…

Does organ preservation after cCR with TNT🧨 affect distant metasases rate in rectal ca? Results of NO-CUT🚫🔪trial @TheLancetOncol show 26% of pMMR/MSS pts achieve cCR and distant RFS 95% in nonop group vs 74% SOC @OHSUKnight @tsikitis @HKennecke sciencedirect.com/science/articl…

Ten steps towards better perioperative intravenous fluid therapy ➡️ doi.org/10.1093/bjs/zn… 💧 IV fluids are drugs — both deficit and overload worsen outcomes, yet perioperative prescribing is often overlooked and delegated to juniors 🩺 The paper stresses ABCDE assessment and clear indication (resuscitation, replacement, maintenance), plus better pre-op hydration with “SipTilSend” ⚖️ Intraoperatively, it advocates balanced crystalloids over 0.9% saline, low-rate background infusions, and goal-directed boluses to avoid salt–water overload 🩸 For bleeding, early 1:1:1 blood product transfusion is advised 🥤 Post-op care focuses on tailored maintenance (≤2–2.5 L/day), early oral intake, and aiming for near-zero or negative fluid balance to reduce complications Work by Michael Ess, Dileep N Lobo @DL08OMD #SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @BJSAcademy @young_bjs @BJSOpen @des_winter @evanscolorectal @robhinchliffe1 @bplwijn @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol @ksoreide #some4hpb #some4tpl @DPCG_official @pancreatitis_nl @PancreasClub #PancreasClub2023 #PancreaticCancer #Pancreatitis #HCC @PanCAN#PanCANawareness @EurPancClub @P_C_E_ @dice_europe #PancreaticCancer#cholangiocarcinoma #colorectalsurgery #StepUp4CRC @FightCRC @ACPGBI #ERAS @dice_europe #Crohn #proctology @Dukes_Club @ACPGBI_EduTrain @AECP_FAECP @PelvExGroup @escp_tweets @YouESCP #TeachMeColoproctology #Some4COLoprocto

🧠 You can shrink the tumour—but not the tumour bed. New RAPIDO analysis in BJS 2025 shows why small margins after TNT can turn dangerous 👇 💡 Trial: RAPIDO (n = 920, LARC) 🎯 TNT = 5×5 Gy + 6 CAPOX / 9 FOLFOX → TME vs CRT = 25–28×1.8–2 Gy + capecitabine → TME 📊 8-year results: • LRR 10.8% (TNT) vs 5.8% (CRT) → HR 1.91 • Spike seen only after sphincter-preserving surgery (SPS)  → 12.1% (TNT) vs 4.8% (CRT) (HR 2.6) • 🚨 If distal margin ≤ 10 mm → 25.4% (TNT) vs 1.8% (CRT) 💥 (HR 15.5) 🔍 Why? TNT causes tumour shrinkage but leaves scattered viable cells in the original tumour bed. ✂️ Cutting “too close” (<1 cm) may slice through microscopic disease → higher local recurrence. 🇸🇪🇳🇱 Geography tells the story: Sweden = more APR → no difference Netherlands = more SPS & tight margins → higher TNT LRR 🩻 Takeaway: TNT reduces distant mets ✅ but may raise local relapse if DRM ≤ 1 cm ⚠️ ➡️ Surgeons must factor in baseline tumour bed, not just post-TNT shrinkage. 📖 Prata I et al. Br J Surg 2025 🔗 doi.org/10.1093/bjs/zn… #OncoTwitter #ColorectalCancer #RectalCancer #RadOnc #Surgery @OncoAlert @esmo_open @BJSurgery @myESMO

Is Minimally Invasive Surgery at an Inflection Point? facs.org/for-medical-pr…

#Rise of the #Robots 🦾 in the Netherlands 🇳🇱 GI surgery @AnnalsofSurgery 😳 How does this compare to your country? Data? Nationwide use 🦾 per organ among 77,361 resections (2014-2023): ✅ pancreas 1% to 33% ✅ thoracic 3% to 11% ✅ colon 6% to 14% ✅ rectum 19% to 45% ✅ liver 10% to 25% ✅ esophageal 33% to 40% ↔️ gastric 19% to 19% ⏩️ journals.lww.com/annalsofsurger…

Interesting paper questioning the need for routine type and screen by @KhanSidrah786 from her year at @MayoClinicSurg colorectal surgery fellowship

Which pts undergoing elective colorectal resections need a preop type & screen? Find out exclusively in #DCRJournal: bit.ly/4fZIeIX

RA-CUSUM charts offer a powerful tool to track surgeon performance in rectal cancer cases—spotting trends in complications, operative time, and outcomes in real time. journals.lww.com/annalsofsurger…

This study shows how RA-CUSUM can identify high and low outliers in robotic rectal surgery—offering a data-driven path to continuous surgical improvement. journals.lww.com/annalsofsurger…

For the 36th consecutive year since U.S. News & World Report launched its "Best Hospitals" rankings, Mayo Clinic again ranks at the top of the 2025–2026 list. Read more: mayocl.in/4716aJm

For dMMR colon cancer, FOLFOX + atezolizumab per ATOMIC is now incorporated into the NCCN Guidelines. @MayoCancerCare @ALLIANCE_org @ASCOPost @CCAlliance @RueschCenter @FightCRC

Great work team @JyiChengNg @RichardSassun @AnnaclaraS65 @MayoClinic @MayoCancerCare @MayoClinicSurg

Vacation: #sailing with Capt Marco in #Sardinia fantastic water, beaches, mountains, food and Friends. @DFerrariMD @RichardSassun @tommyv1992 @EricaCento

Safe Same-Day and Short-Stay Stoma Closures Revolutionize Care by Ferrari D, Violante T (...) Larson DW et 7 al. in J Gastrointest Surg 🪡 read our summary 👉 stitches.today/2025/06/10/saf… 📖 read the article: sciencedirect.com/science/articl…

Spectacular wedding of Roberta and Tommaso in #sardinia. To my friend and colleague may your marriage be blessed and your new surgical practice in Bologna equally blessed. Love and respect to @tommyv1992 @DFerrariMD @EricaCento @AnnaclaraS65 @RichardSassun

Game-changer at #ASCO25 🔥 Pre-plenary press release!! ATOMIC is the most important adjuvant study yet for MSI-H colon cancer—and it’s practice-changing. 🧬 Stage III dMMR colon cancer 🧪 Atezolizumab + mFOLFOX6 vs mFOLFOX6 alone 💥 3-yr DFS: 86.4% vs 76.6% ⚖️ HR 0.50 | p < .0001 Across subgroups, benefit was consistent. Toxicity was manageable. Immunotherapy has arrived in the adjuvant setting! MSI-H colon cancer now has a new standard overnight. ❓ But do all patients still need chemo? @ASCO @OncoAlert @JCO_ASCO @oncoalert @oncbrothers 🎙️ Featured Voices: @yekeduz_emre @DRBakaloudiMD @AndreaAnampaG @ReginaBarCar @cwspeers @FunchainMD @MKnoll_MD @bavilima @KrishanJethwa @cancerassassin1 @ReneeSaliby @MikeSerzanMD @OncBrothers @coloncancergal @ShannonWestin @SuyogCancer @supriyadocc @UGrewalMD @coffeemommy @RyanNipp @realbowtiedoc @crisbergerot